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The NHS Cancer Plan asserts that ‘patients in the UK tend to have
more advanced disease by the time their treatment begins than
their counterparts in other European countries. This is thought to
explain at least some of the poorer survival rates seen for some
cancers in the UK’. Although no bibliography is provided with
the NHS Cancer Plan, these observations are clearly based on the
findings of the ‘high-resolution’ studies undertaken as part of the
EUROCARE project; these studies, which collected detailed
information on patient and disease related prognostic factors, were
intended to provide an explanation for the survival differentials
reported in EUROCARE II, a report which has contributed to an
impression of inadequate care of cancer patients in the UK
(Berrino et al, 1999). The first of these high-resolution (HR)
studies, which describes the survival of patients with colorectal
cancer diagnosed during 1989–91, has now been published, with
the following conclusion: ‘the wide differences across Europe in
colorectal cancer survival depend to a large extent on differences
in stage at diagnosis. There are wide variations in diagnostic and
surgical practices. There was a twofold range in the risk of death
from colorectal cancer even after adjustment for surgery and
disease stage’ (Gatta et al, 2000). 
As the NHS Cancer Plan places considerable importance on
achieving parity with the best cancer care in Europe, a detailed
critique of the methodological problems revealed by this study,
from the perspective of the UK, would appear timely. 
Representativeness of cases included in the high
resolution study 
We first consider how representative of EUROCARE II are the
countries included in the HR study. Whereas 47 cancer registries
in 17 countries contributed to EUROCARE II, only 11 registries in
6 countries were included in the HR study. It is not clear how
registries were identified for inclusion: no Scandinavian registry
contributed cases, nor did any in Austria, Switzerland or Germany,
countries which had among the highest survival rates for
colorectal cancer in EUROCARE II; the HR study also includes a
Spanish registry (Granada) which did not contribute cases of
colorectal cancer to EUROCARE II, but includes none of the four
Spanish registries which did. 
We next consider how representative of EUROCARE II are the
sample of cases submitted to the HR study by each cancer registry.
Each registry was asked to provide a sample of at least 200 consec-
utive cases: a total of 2270 cases diagnosed between 1989 and
1991 were submitted; Thames, the cancer registry with the largest
catchment population included in this study, failed to contribute
the stated minimum number, as did Granada. 
The investigators address the issue of representativeness by
comparing the mean age and survival of the cases provided for the
HR study with the corresponding values in EUROCARE II. 
For all but three registries, the survival estimate for the cohort
submitted to the HR study was very similar to that submitted to
EUROCARE II (Table 1); the more substantial differences
observed for the Mersey (44% vs 37%) and Rotterdam (48% vs
56%) cohorts are attributed to random variation, although the
results of significance testing are not presented. 
The 3-year survival rate reported for Modena (59%) in the HR
study merits detailed consideration because it is the highest for any
of the registries included in this study and is substantially different
from that reported for the same registry in EUROCARE II (47%);
we infer from the absence of any comment on random variation
that in this case the difference is statistically significant. 
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HR study was confined to cases from the town of Modena,
whereas the analysis reported in EUROCARE II included cases
from the province of Modena. This explanation must be ques-
tioned because the Modena cancer registry, which covers the
province of Modena with its population of 660 000, was only
established in 1988 (Parkin et al, 1997). In EUROCARE II,
however, Modena is listed as providing colorectal cases for the 5-
year period 1984–89. It is difficult to avoid the conclusion that the
cases contributed to both the EUROCARE II report and the HR
study were not from the town and province of Modena respec-
tively, as suggested, but were instead from the Modena colorectal
cancer registry, established in 1984 in District 16 of the Region
Emilia–Romagna; this district includes Modena and 10 smaller
towns with a total population of 262 000 residents, which is almost
identical in size to the reference population cited in EUROCARE
II (Ponz de Leon et al, 1993). 
A reanalysis of the tabulated data presented in EUROCARE II
and in the HR study reveals a possible alternative explanation for
the difference in survival between the Modena cohorts included in
these reports: compared with the EUROCARE II cohort there was
a significantly lower mortality rate at 1 month after diagnosis in
the HR study (2% vs 5%, Fisher’s exact test P = 0.016). Were this
to reflect a failure to include in the HR cohort all patients with
advanced disease, it might provide an explanation for the
extremely high survival at 3 years observed in this cohort for both
unresected cases (25%) and for those with advanced disease
(25%). 
The HR study also suggests that medical care may be better in
Modena than elsewhere in Italy; this may be the case, but among
the Italian registries, Modena did not have the best survival rates
for either colon or rectal cancer either in EUROCARE II or in the
cited study on regional differences in cancer survival in Italy
(Gatta et al, 1997). 
We have some reservations about the representativeness of
cases submitted to the HR study by the two English registries. The
authors report that the 3-year survival of cases contributed to
EUROCARE II was 40% for Thames and 37% for Mersey; in
contrast, for cases included in the HR study, residents of the
Mersey region with colorectal cancer had a better survival than
those from the Thames region (44% vs 38%). Furthermore,
compared with the Thames cohort of colorectal cancers included
in EUROCARE II, that in the HR study had significantly more
deaths within one month of diagnosis (16% vs 9%, Fisher’s exact
test P = 0.0029). 
In addition, a previous study carried out within the EURO-
CARE network, reported surgical resection rates for all colorectal
cancers incident in 1987 in 15 European populations, for whom
relatively complete data on treatment were available; 8 of the
registries participating in this earlier study also contributed cases
to the HR analysis (Gatta et al, 1996). With the exception of
Cracow and Thames, surgical resection rates are higher in the HR
than in the earlier study; the largest increase was observed for
cases contributed by the Mersey registry, from 66% to 82%. A
formal statistical comparison is not possible because the earlier
study reports an age adjusted rate and the latter a crude rate; the
difference, however, is unlikely to be explained by age adjustment
because the more recent Mersey cohort includes a greater propor-
tion of cases aged 75 years and over. It is also surprising, given the
general impression of inadequate care of cancer patients in the UK
left by the EUROCARE reports, that in the HR study the propor-
tion of patients who underwent surgery and who had this as an
emergency procedure was lowest in the sample contributed by the
Mersey registry. 
Comparison of survival rates 
When estimating survival from population based data it is not
always possible to decide from death certificates whether a patient
has died from cancer or from an unrelated cause. To overcome this
problem it is usual to include all deaths in the analysis but to allow
for other causes of death by calculating the relative survival rate,
defined as the ratio of the observed survival rate to the survival
rate which would be expected in an underlying population simi-
larly constituted with respect to age and sex. 
In the HR study, the investigators chose to present observed
rather than relative survival rates. EUROCARE II reports both
observed and relative survival rates, and the more detailed site-
specific reports based on EUROCARE II data which appeared in
the European Journal of Cancer present relative survival rates
(Gatta et al, 1998). The authors do state that multiple regression
analysis of relative survival rates, the conventional analysis in this
situation, was carried out, but only to check the proportional
hazards analysis presented. The authors justify the presentation of
observed rather than relative survival rates by arguing that at 3
years, competing causes of mortality are likely to have a minimal
impact on survival estimates; and present the minimum (1.4%) and
maximum (1.8%) differences between observed and relative
survival estimates for registries included in this analysis. 
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Table 1 Comparison of observed survival at 3 years for registries
participating in the high resolution (HR) and EUROCARE II studies 
Observed survival at 3 years (%) 
Registry HR study EUROCARE II 
Varese 49 50 




Rotterdam 48 56 
Eindhoven 55 51 
Granada 46 n/a2
Mersey 44 37 
Thames 38 40 
Cracow 25 22 
1Registries not separately identified in source; 2Registry not included in
EUROCARE II; Source: Gatta G et al (2000) Gut 47: 533–538. 
Table 2 A comparison of the observed and relative survival rates at 3 years
for colon cancer and cancer of the rectum reported in EUROCARE II 
Colon Rectum 
3-year observed  3-year relative 3-year observed  3-year relative 
survival (%) survival (%) survival (%) survival (%)
Italy 46 53 47 53 
France 50 58 51 58 
Netherlands 54 62 53 60 
Spain 47 53 44 49 
England 39 46 41 48 
Poland 25 29 27 31 
}
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comparison using EUROCARE II data, of the observed and rela-
tive survival rates at 3 years for patients with colon and rectal
cancer, in countries which also contributed cases to the HR study,
reveals substantially greater differences (Table 2). Reasons for this
disparity are not immediately obvious. 
Interpretation 
When considering the interpretation of these results, it should be
pointed out that considerable caution must be exercised when
comparing stage-specific survival rates across registries, when not
only does the proportion of unstaged cases vary from 4% to 39%,
but the survival of unstaged cases also varies substantially, from
8% to 54%. The conflation of Dukes’ stage A and B tumours is
counterintuitive, given that these stages have different survival
rates. The authors’ characterization of both Dukes’ stage A and B
tumours as being confined to the bowel wall, is inconsistent with
the classification system proposed by Dukes (Dukes, 1932). 
The authors of the HR study conclude that ‘across Europe
survival differences were large but narrowed when corrections for
stage were applied.’ Were the result for Cracow, an outlier in
almost all respects, ignored, then the relative risk of death
compared to Varese (reference category) adjusted for age, sex and
site but prior to adjustment for stage varied across the remaining
registries from 0.73 to 1.41, and after adjustment for stage, from
0.76 to 1.37. Inspection of the range of relative risks before and
after adjustment for an explanatory variable is a simplistic method
for considering the amount of variation thus explained, but even
using this method, the effect of stage does not appear to be great. 
The authors also suggest that after appropriate correction for
stage,  ‘...in the Thames region, survival became similar to the
other Western European registries, suggesting that the main reason
for the low survival in the Thames area was late stage at diag-
nosis.’ This is demonstrably not the case: after controlling for age,
sex and site, further adjustment for stage had a minimal impact on
the relative risk of death for cases contributed by the Thames
registry (from 1.41 to 1.37); this remained statistically significant.
The authors conclude that ‘the large differences in the survival of
unresected patients [0% to 25% three year survival] most likely
reflect different therapeutic approaches to patients with little
chance of being cured.’ We disagree. We would of course like to
believe that the 25% survival rate at 3 years achieved in unresected
patients in Modena is attainable elsewhere, but are not convinced
that such an outcome was plausible during the period when these
cases were diagnosed. We would suggest that either misdiagnosis
or a failure to ascertain all deaths is a more likely explanation. The
final model presented in the HR study does suggest that with the
exception of Cracow, there is no significant difference in outcome
in surgically resected cases. 
DISCUSSION 
The high-resolution study has substantial methodological flaws
and provides no convincing evidence that stage at diagnosis can
explain, for colorectal cancer at least, the differences in survival
between the UK and other countries in Europe. 
The lack of consistency across the different publications from
the EUROCARE project is particularly disturbing because the
NHS Cancer Plan promises ‘the fastest improvement in cancer
services anywhere in Europe over the next five years. By 2010, our
five year survival rates for cancer will compare with the best in
Europe.’ This promise may offer a hostage to fortune because, as
we have previously argued, for some cancer registries which
contributed to EUROCARE II, survival rates were likely to be
inflated because of the failure to register all cases of advanced
disease and/or the failure to ascertain deaths in registered cases
(Prior et al, 1998; Moran et al, 2000). Furthermore, whereas there
is complete coverage of cancer registration in the UK, many of the
countries contributing to EUROCARE II were represented by
registries which covered only a fraction of their total population.
The authors of EUROCARE II concede that their experience may
not be entirely representative of cancer survival in those countries
(Berrino et al, 1999). 
Careful thought therefore needs to be given to identifying coun-
tries with which the UK can usefully compare itself. Ideally, these
countries should have mature cancer surveillance programmes
with total population coverage, systems in place for the collection
and collation of data from multiple sources in order to maximize
case ascertainment, and access and efficient linkage to death
certificates; the Scandinavian countries fulfil all of these criteria
and all, with the exception of Denmark, have better survival rates
than the UK for many sites of cancer. 
However an assessment of the progress made by the UK
towards convergence with its European comparators should not
wait until 5-year cancer survival rates become available in 2010.
Sub-optimal care needs to be promptly identified and rectified;
those lessons which can be learnt from comparators need to be
learnt as soon as possible. 
One way forward would be to focus population-based compar-
isons on those processes of care which can be clearly linked to
outcome, for example the use of adjuvant chemotherapy in the
management of patients with bowel cancer. It should be noted that
for those sites of cancer for which some countries have established
screening programmes, for example breast cancer, comparisons
based on cancer survival rates can be misleading. 
A rolling audit programme based on genuinely representative
samples of cases would provide more useful information on how
the delivery of cancer services in the UK might be improved. Such
a development might be timely, given the improvement in
completeness of information on stage of disease routinely captured
by the UK registries, and the proposed expansion of the minimum
dataset which they collect. For the first time it would also provide
a credible population-based comparison of the distribution of
patient and disease related prognostic factors in countries with a
range of cancer survival rates; this intelligence is critical to the
future development of the UK cancer control strategy. 
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